Navigation Links
Bioniche Presents Pre-Clinical Research at Two International Conferences

BELLEVILLE, ON, May 23 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, reports two presentations made by its researchers at international conferences this week.

Presentation to the Annual Meeting of the American Urological Association

----------------------------------------------------------------------- --

Bioniche Life Sciences Inc. was among the presenters at the Annual Meeting of the American Urological Association (AUA) held in Orlando, Florida, U.S.A. this week. The presentation, entitled, "Quantification of chromosomal aberrations by multiprobe fluorescence in situ hybridization profile (FISH) of 9 human bladder cancer cell lines commonly used in urological research", was made by Sonia Menard, Research Associate in the Bioniche pre-clinical research and development team.

The study was carried out in conjunction with the Cytogenetic Laboratory, Miller School of Medicine, University of Miami, Miami, Florida, U.S.A. Using fluorescence in situ hybridization (FISH), the chromosomal status of bladder cancer cell lines commonly used in bladder cancer research was determined. The results of the study showed that the nine bladder cancer cell lines studied, which were originally derived from low- to high-grade bladder tumours, were actually representative of high-grade bladder cancer.

"Bioniche has previously evaluated the activity of its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) against bladder cancer cell lines derived from low- and high-grade tumours, and has shown comparability of anticancer activity," said Dr. Nigel C. Phillips, Chief Scientific Officer at Bioniche Life Sciences Inc. "The Company has also previously reported the anticancer activity of MCC against primary bladder cancer cell cultures, where a uniform activity profile was observed that was independent of tumour grade."

Presentation to Immunopotentiators in Modern Vaccines Conference


Bioniche Life Sciences Inc. was invited to present at the Immunopotentiators in Modern Vaccines Conference in Montego Bay, Jamaica, this week. The presentation, entitled, "Mycobacteria-derived immunopotentiating molecules and their application in vaccine development", was made by Dr. Nigel C. Phillips, Chief Scientific Officer of Bioniche Life Sciences Inc.

Dr. Phillips discussed the development pathway from MCC to the Company's synthetic oligonucleotides, and reviewed their immune stimulatory and immune adjuvant activity. "The data presented clearly demonstrate that the Company's proprietary, synthetic, non-CpG containing oligonucleotides have immune stimulant activity (cytokine induction and activation of antigen presenting cells)," said Dr. Phillips. "This is in addition to the previously reported direct anticancer activity. They appear to have considerable potential as vaccine adjuvants, as demonstrated in proof-of-principle animal studies using human hepatitis B surface antigen. Mechanistic studies indicate that they have a unique mode of action in their ability to stimulate immune responses."

About the Oligonucleotide Technology Platform

In 2000, Bioniche announced the discovery of a new class of molecules with potential anticancer activity, referred to by the Company under the trademark, "Oligomodulator(TM)". This new class of molecules with potential clinical anticancer activity and immune modulating properties is composed of short non-antisense DNA oligonucleotides that appear to possess a range of novel pharmacological activities.

About MCC

MCC is a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. It is formulated as Urocidin(TM) for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into contact with immune system cells and bladder cancer cells. MCC is undergoing preclinical evaluation as a treatment for peritoneal carcinomatosis associated with colon and ovarian cancer.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
11. Bioniche Reports Fiscal 2008 Second Quarter
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: